HALEOS LABS LIMITED (HALEOSLABS) financials

HALEOS LABS LIMITED (HALEOSLABS) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates[1]

Market Cap: ₹463Cr.
Current Price: ₹1,532
Stock P/E: 29.2
ROE: 8.64%
ROCE: 10.6%
Book Value: ₹710
Dividend Yield: 0.10%
52W High / Low: ₹1,778/1,091

In Jun 2026, HALEOS LABS LIMITED (HALEOSLABS) reported sales ₹67.83 Cr and net profit ₹3.24 Cr.

Annual TTM: sales ₹290 Cr, net profit ₹16 Cr.

Shareholding: Promoters 72.10% (Sep 2026), FIIs 0.00% (Sep 2026), DIIs 0.31% (Sep 2026), Public 27.58% (Sep 2026), No. of Shareholders 6,765% (Sep 2026).

HALEOSLABS quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	78.50	82.88	85.43	79.04	77.84	80.72	63.38	67.83
Expenses	66.71	69.81	79.83	68.21	67.04	69.16	57.18	58.19
Operating Profit	11.79	13.07	5.60	10.83	10.80	11.56	6.20	9.64
OPM %	15.02%	15.77%	6.56%	13.70%	13.87%	14.32%	9.78%	14.21%
Other Income	1.26	0.06	2.20	1.01	0.44	0.08	0.97	0.46
Interest	1.92	1.96	1.84	1.73	1.51	1.46	1.34	1.81
Depreciation	2.57	2.56	2.62	2.63	2.68	2.69	2.66	3.01
Profit before tax	8.56	8.61	3.34	7.48	7.05	7.49	3.17	5.28
Tax %	29.79%	27.64%	19.76%	31.02%	29.36%	27.77%	29.65%	38.64%
Net Profit	6.01	6.23	2.68	5.16	4.98	5.41	2.23	3.24
EPS in Rs	19.88	20.61	8.86	17.07	16.47	17.89	7.38	10.72
Raw PDF	—	—	—	—	—	—	—	—

HALEOSLABS profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	257	260	346	315	300	333	301	290
Expenses	233	230	314	289	265	289	260	252
Operating Profit	24	30	31	26	35	44	41	38
OPM %	9%	11%	9%	8%	12%	13%	13%	13%
Other Income	2	1	14	5	4	4	1	2
Interest	5	5	5	5	9	8	6	6
Depreciation	7	7	8	8	10	10	11	11
Profit before tax	13	19	33	18	19	30	25	23
Tax %	31%	32%	23%	28%	32%	29%	29%	—
Net Profit	9	13	25	13	13	21	18	16
EPS in Rs	30.26	43.56	83.95	43.73	43.23	70.68	58.81	52.46
Dividend Payout %	0%	3%	2%	3%	3%	2%	3%	—

HALEOSLABS balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	3	3	3	3	3	3	3	3
Reserves	102	110	123	148	161	173	194	212
Borrowings	47	50	45	62	87	92	82	95
Other Liabilities	98	66	101	99	86	80	80	94
Total Liabilities	251	229	272	312	337	348	358	403
Fixed Assets	88	94	101	99	140	138	150	190
CWIP	1	2	3	21	1	6	0	1
Investments	26	26	26	23	23	23	23	23
Other Assets	135	106	142	169	174	181	184	189
Total Assets	251	229	272	312	337	348	358	403

HALEOSLABS cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	27	14	22	-15	5	15	28	38
Cash from Investing Activity	-43	-13	-6	-7	-28	-14	-14	-49
Cash from Financing Activity	18	-2	-8	15	23	-1	-14	11
Net Cash Flow	2	-1	8	-8	-1	0	0	0
Free Cash Flow	5	1	14	-30	-24	1	14	-11
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	103%	70%	88%	-23%	31%	51%	82%	111%

HALEOSLABS shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	71.40%	71.40%	71.40%	71.40%	71.79%	72.10%	72.10%	72.10%
FIIs	0.00%	0.00%	0.03%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.00%	0.00%	0.00%	0.03%	0.29%	0.30%	0.31%	0.31%
Public	28.59%	28.60%	28.56%	28.57%	27.91%	27.59%	27.58%	27.58%
No. of Shareholders	7,626	7,479	7,412	7,521	7,125	6,937	6,859	6,765

HALEOSLABS key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	39	31	42	36	53	60	71	66
Inventory Days	117	138	154	143	154	168	131	180
Days Payable	133	91	147	124	105	111	99	139
Cash Conversion Cycle	23	78	48	54	102	116	102	107
Working Capital Days	20	27	31	44	65	61	57	57
ROCE %	22%	12%	14%	13%	9%	11%	14%	11%

HALEOSLABSUpdated 17 Oct 2026, 22:43

Haleos Labs Limited

HALEOSLABSUpdated 17 Oct 2026, 22:43

Market Cap

₹463Cr.

Current Price

₹1,532

High / Low

₹1,778/1,091

Stock P/E

29.2

ROE8.64%

ROCE10.6%

Book Value₹710

Face Value₹10.0

Dividend Yield0.10%

About

Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	74.56	1.82	69.43	0.58	2.53	1.36	48.53	0.7	2.32
Sep 2023	67.84	2.48	58.36	0.33	2.55	4.78	34.73	3.12	10.32
Dec 2023	71.23	2.04	62.21	0.64	2.55	5.07	34.71	3.31	10.95
Mar 2024	86.37	2.56	75.56	2.28	2.62	7.91	24.91	5.93	19.61
Jun 2024	86.57	2.16	72.8	0.43	2.5	9.54	32.29	6.46	21.37
Sep 2024	78.5	1.92	66.71	1.26	2.57	8.56	29.79	6.01	19.88
Dec 2024	82.88	1.96	69.81	0.06	2.56	8.61	27.64	6.23	20.61
Mar 2025	85.43	1.84	79.83	2.2	2.62	3.34	19.76	2.68	8.86
Jun 2025	79.04	1.73	68.21	1.01	2.63	7.48	31.02	5.16	17.07
Sep 2025	77.84	1.51	67.04	0.44	2.68	7.05	29.36	4.98	16.47
Dec 2025	80.72	1.46	69.16	0.08	2.69	7.49	27.77	5.41	17.89
Mar 2026	63.38	1.34	57.18	0.97	2.66	3.17	29.65	2.23	7.38
Jun 2026	67.83	1.81	58.19	0.46	3.01	5.28	38.64	3.24	10.72

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	0	0	0	0	0	0	—	0	—
Mar 2016	0	0	0	0	0	0	—	0	—
Mar 2017	218	6	189	2	6	18	30	13	—
Mar 2018	213	4	200	3	6	6	-2	6	21.5
Mar 2019	344	5	312	2	6	24	30	17	55.01
Mar 2020	257	5	233	2	7	13	31	9	30.26
Mar 2021	260	5	230	1	7	19	32	13	43.56
Mar 2022	346	5	314	14	8	33	23	25	83.95
Mar 2023	315	5	289	5	8	18	28	13	43.73
Mar 2024	300	9	265	4	10	19	32	13	43.23
Mar 2025	333	8	289	4	10	30	29	21	70.68
Mar 2026	301	6	260	1	11	25	29	18	58.81
TTM	290	6	252	2	11	23	—	16	52.46

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	72.1%
DIIs	0.31%
Public	27.58%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	70.68%	0%	0%	29.31%
Mar 2024	71.19%	0%	0%	28.81%
Jun 2024	71.4%	0.01%	0%	28.59%
Sep 2024	71.4%	0.02%	0%	28.57%
Dec 2024	71.4%	0%	0%	28.59%
Mar 2025	71.4%	0%	0%	28.6%
Jun 2025	71.4%	0.03%	0%	28.56%
Sep 2025	71.4%	0%	0.03%	28.57%
Dec 2025	71.79%	0%	0.29%	27.91%
Mar 2026	72.1%	0%	0.3%	27.59%
Jun 2026	72.1%	0%	0.31%	27.58%
Sep 2026	72.1%	0%	0.31%	27.58%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	0.01	0	0	0	0	0	0	0	0	0
Mar 2016	0.01	0	0	0	0	0	0	0	0	0
Mar 2017	0.01	82	26	67	175	73	0	0	102	175
Mar 2018	3	85	27	61	177	69	7	5	95	177
Mar 2019	3	102	47	98	251	88	1	26	135	251
Mar 2020	3	110	50	66	229	94	2	26	106	229
Mar 2021	3	123	45	101	272	101	3	26	142	272
Mar 2022	3	148	62	99	312	99	21	23	169	312
Mar 2023	3	161	87	86	337	140	1	23	174	337
Mar 2024	3	173	92	80	348	138	6	23	181	348
Mar 2025	3	194	82	80	358	150	0	23	184	358
Mar 2026	3	212	95	94	403	190	1	23	189	403

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	0	0	0	0
Mar 2016	0	0	0	0
Mar 2017	20	-8	-12	0
Mar 2018	8	-7	-1	0
Mar 2019	27	-43	18	2
Mar 2020	14	-13	-2	-1
Mar 2021	22	-6	-8	8
Mar 2022	-15	-7	15	-8
Mar 2023	5	-28	23	-1
Mar 2024	15	-14	-1	0
Mar 2025	28	-14	-14	0
Mar 2026	38	-49	11	0

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	—	—	65	46	39	31	42	36	53	60	71	66
Inventory Days	—	—	133	135	117	138	154	143	154	168	131	180
Days Payable	—	—	168	122	133	91	147	124	105	111	99	139
Cash Conversion Cycle	—	—	30	60	23	78	48	54	102	116	102	107
Working Capital Days	—	—	43	41	20	27	31	44	65	61	57	57
ROCE %	0%	—	46%	9%	22%	12%	14%	13%	9%	11%	14%	11%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of HALEOS LABS LIMITED (HALEOSLABS)?

The reported market capitalisation for HALEOS LABS LIMITED (HALEOSLABS) is ₹463Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of HALEOSLABS?

The current price shown for HALEOS LABS LIMITED (HALEOSLABS) on Fincrux is ₹1,532 with a 52-week high/low of ₹1,778/1,091.

What is the P/E ratio of HALEOS LABS LIMITED (HALEOSLABS)?

The stock P/E for HALEOS LABS LIMITED (HALEOSLABS) is 29.2 on Fincrux, with ROE at 8.64% and ROCE at 10.6%.

What were HALEOSLABS latest quarterly results?

For Jun 2026, HALEOS LABS LIMITED (HALEOSLABS) reported sales ₹67.83 Cr and net profit ₹3.24 Cr (figures in ₹ crore unless noted).

What are HALEOSLABS annual sales and net profit?

For TTM, HALEOS LABS LIMITED (HALEOSLABS) shows sales of ₹290 Cr and net profit of ₹16 Cr on the Fincrux profit & loss statement.

Who owns HALEOS LABS LIMITED (HALEOSLABS)?

Latest shareholding for HALEOS LABS LIMITED (HALEOSLABS) on Fincrux: Promoters 72.10% (Sep 2026), FIIs 0.00% (Sep 2026), DIIs 0.31% (Sep 2026), Public 27.58% (Sep 2026), No. of Shareholders 6,765% (Sep 2026).

Where can I find HALEOS LABS LIMITED (HALEOSLABS) financials?

HALEOS LABS LIMITED (HALEOSLABS) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show HALEOSLABS balance sheet and cash flow?

Yes. The HALEOS LABS LIMITED (HALEOSLABS) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 17 October 2026 at 22:43